Important update on the Risk Management Plan of Jinarc® (tolvaptan)

A Dear Healthcare Professional Letter has been issued by Otsuka Pharmaceuticals (Singapore) Pte. Ltd. to inform healthcare professionals of an update to the Risk Management Plan (RMP) for Jinarc® (tolvaptan) to streamline the supply process. The restricted distribution programme, which was introduced to mitigate risk of liver injury, will be removed. This change will allow hospitals, pharmacies, and clinics to hold stocks of Jinarc® and enable same-day dispensing following physician consultation. Other risk minimisation measures under the Jinarc® RMP will remain in place. Healthcare professionals are advised to refer to the letter for information on the use of Jinarc® and details on the remaining risk minimisation measures to follow. Please refer to the letter for details.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.